Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experience

• Published in: Cancer 2001-09, Vol.92 (5), p.1092-1100
• Main Authors: VLASTOS, Georges, MIRZA, Nadeem Q, MERIC, Funda, HUNT, Kelly K, KUERER, Henry M, AMES, Frederick C, ROSS, Merrick I, BUCHHOLZ, Thomas A, HORTOBAGYI, Gabriel N, EVA SINGLETARY, S
• Format: Article
• Language: English
• Subjects: Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Breast Neoplasms - therapy; Comorbidity; Female; Gynecology. Andrology. Obstetrics; Humans; Lymph Node Excision; Mammary gland diseases; Mastectomy, Segmental; Medical sciences; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Rate; Tumors
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/1097-0142(20010901)92:5<1092::AID-CNCR1425>3.0.CO;2-P

Although almost half of all incidents of breast carcinoma occur in women age > or = 65 years, not enough is known about appropriate care for patients in this age group. The objective of the current study was to evaluate the role of breast conservation therapy in the management of breast carcinoma in women age > or = 65 years. From 1970 to 1994, 1325 patients with carcinoma of the breast were treated with breast conservation therapy (segmental mastectomy and radiation therapy with or without axillary lymph node dissection) at The University of Texas M. D. Anderson Cancer Center. From this patient group, the authors identified 184 elderly women (> or = 65 years) with Stage 0-III disease at the time of diagnosis. The median patient age was 70 years (range, 65-88 years). The distribution of disease by stage among the women was Stage 0 disease in 12 patients (7%), Stage I disease in 107 patients (58%), Stage II disease in 63 patients (34%), and Stage III disease in 2 patients (1%). Comorbid conditions that may have influenced treatment planning were reported in 91 patients (50%). An axillary lymph node dissection was performed in 135 patients (73%), with positive axillary lymph nodes found in 30 patients (22%). Adjuvant chemotherapy was given to 10 patients (5%), and tamoxifen therapy was given to 63 patients (34%). Complications from treatment were reported in 24 patients (13%). With a median follow-up of 7.3 years (range, 0.25-23.5 years), 9 patients developed locoregional disease recurrence (5%), 10 patients developed contralateral breast carcinoma (5%), and 21 patients developed distant metastasis (11%). At last follow-up, 113 patients (61%) were alive, 15 patients (8%) were dead of disease, and 56 patients (30%) were dead of other causes. The 5-year and 10-year disease specific survival rates were 96% and 91%, respectively. Breast conservation therapy with segmental mastectomy and postoperative radiation therapy with or without axillary lymph node dissection provides excellent local control and disease free survival in elderly women with breast carcinoma. This treatment should be considered as the standard of care for elderly patients without severe comorbid disease.